RecruitingNot ApplicableNCT06761274

Study of Epigenetic and Inflammatory Markers of Accelerated Biological Ageing in the Follow up of Patients With Hodgkin's Lymphoma

Study of Epigenetic and Inflammatory Markers of Accelerated Biological Ageing in the Follow-up of Patients With Hodgkin's Lymphoma in Complete Remission for at Least 2 Years

Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Enrollment

200 participants

Start Date

Nov 3, 2022

Study Type

INTERVENTIONAL

Conditions

Hodgkin Lymphoma in Remission

Summary

Study design: It is a monocentric and exploratory study, experimental on human tissues in vitro which involves the analysis of peripheral blood in patients with Hodgkin's lymphomas with the following characteristics: * in complete remission for at least two years after first-line therapy with stage IIb, III or IV at onset (Ann Arbor classification). * newly diagnosed (stage IIb, III or IV, Ann Arbor Classification).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is looking at biological markers of aging — specifically in DNA and inflammation — in people who have had Hodgkin's lymphoma. Researchers want to understand whether cancer treatment causes people to age faster at a biological level. **You may be eligible if...** - You are 18 or older - You have Hodgkin's lymphoma at stage IIb, III, or IV - You are either newly diagnosed and about to start treatment, OR you have been in remission for at least two years **You may NOT be eligible if...** - You have been diagnosed with a second cancer at the same time Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERperipheral blood sampling

It is a monocentric and exploratory study, experimental on human tissues in vitro and similar projects do not exist in the literature. This study involves the analysis of peripheral blood in patients with hodgkin lymphoma with the following characteristics: * in complete remission for at least two years after first-line therapy with stage II b, III or IV at onset (Ann Arbor classification). * newly diagnosed (stage II b, III or IV, Ann Arbor Classification).

Locations(1)

IRCCS Azienda Ospedaliero - Universitaria di Bologna

Bologna, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06761274

Related Trials

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

NCT0179015279 locations